Compugen Regains Nasdaq Compliance, Secures $10M AstraZeneca Milestone

TL;DR

**Compugen is back in Nasdaq's good graces and just bagged $10M from AstraZeneca!**

AI Summary

Compugen Ltd. announced on January 8, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement, removing a significant delisting risk. Additionally, the company is set to receive a $10 million milestone payment from AstraZeneca. This payment was triggered by the dosing of the first patient in AstraZeneca's Phase 3 ARTEMIDE-Bil01 trial for rilvegostomig, an important step in the drug's development for biliary tract cancer. This news is positive for investors as it resolves a compliance issue and brings in substantial non-dilutive cash, signaling progress in its drug pipeline.

Why It Matters

This filing matters because it signals financial stability by resolving a Nasdaq compliance issue and provides a significant cash infusion from a major pharmaceutical partner, validating Compugen's drug development progress.

Risk Assessment

Risk Level: low — The filing indicates positive developments by resolving a compliance issue and securing a milestone payment, reducing immediate risks for the company.

Analyst Insight

A smart investor would view this as a de-risking event and a positive signal for Compugen's financial health and pipeline progress, potentially considering an investment or increasing an existing position.

Key Numbers

• $10 million — milestone payment (payment from AstraZeneca to Compugen for a clinical trial milestone)
• January 8, 2024 — date of announcements (when Compugen issued press releases regarding Nasdaq compliance and the milestone payment)
• 5550(a)(2) — Nasdaq Listing Rule (the specific rule Compugen regained compliance with (minimum bid price))

Key Players & Entities

• Compugen Ltd. (company) — the registrant and recipient of the milestone payment
• Nasdaq (company) — the stock exchange whose listing rules Compugen regained compliance with
• AstraZeneca (company) — the pharmaceutical partner making the $10 million milestone payment
• Anat Cohen-Dayag, Ph.D. (person) — whose quotes are referenced in the Milestone Press Release
• rilvegostomig (other) — the drug candidate in AstraZeneca's ARTEMIDE-Bil01 trial

Forward-Looking Statements

• Compugen's stock price will see a short-term positive reaction due to reduced delisting risk and the cash infusion. (Compugen Ltd.) — high confidence, target: Q1 2024
• The $10 million payment will strengthen Compugen's balance sheet and extend its cash runway. (Compugen Ltd.) — high confidence, target: Q1 2024
• The progress of rilvegostomig in Phase 3 trials will increase investor confidence in Compugen's pipeline. (Compugen Ltd.) — medium confidence, target: Mid-2024

FAQ

Key Financial Figures

• $10 million — herein by reference, announcing that a $10 million milestone payment to the Company from A
• $10 Million — January 8, 2024 – "Compugen to Receive $10 Million Milestone Payment Following Dosing of F

Filing Documents

• zk2430750.htm (6-K) — 12KB
• exhibit_99-1.htm (EX-99.1) — 6KB
• exhibit_99-2.htm (EX-99.2) — 12KB
• image0.jpg (GRAPHIC) — 5KB
• 0001178913-24-000094.txt ( ) — 38KB

Signatures

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. COMPUGEN LTD. Date: January 8, 2024 By: /s/ Eran Ben Dor Eran Ben Dor General Counsel

View Full Filing

View this 6-K filing on SEC EDGAR